TSEN2 Antibody

What is TSEN2 and what cellular functions does it perform?

TSEN2 (tRNA splicing endonuclease subunit 2) constitutes one of the two catalytic subunits of the tRNA-splicing endonuclease complex. This complex is responsible for identification and cleavage of splice sites in pre-tRNA molecules. TSEN2 specifically helps identify and cut sites within tRNA introns so the molecules can be correctly processed, ensuring functional tRNAs are available for translation processes . It cleaves pre-tRNA at the 5'- and 3'-splice sites to release the intron, with isoform 1 likely carrying the active site for 5'-splice site cleavage . Beyond tRNA processing, the tRNA splicing endonuclease is also involved in mRNA processing via its association with pre-mRNA 3'-end processing factors, establishing a link between pre-tRNA splicing and pre-mRNA 3'-end formation .

What applications can TSEN2 antibodies be used for in research?

TSEN2 antibodies are primarily used in several key applications:

These applications enable researchers to investigate TSEN2 expression, localization, and interactions in various experimental contexts .

How do TSEN2 antibodies help in studying tRNA processing mechanisms?

TSEN2 antibodies enable researchers to visualize and quantify this essential component of the tRNA splicing machinery. By using techniques like immunoprecipitation with TSEN2 antibodies, researchers can isolate the entire tRNA splicing endonuclease complex to study its composition and interactions with other cellular components . This approach has been critical in understanding assembly pathways of the complex, including the formation of TSEN2-TSEN54 dimers that serve as intermediates in complex assembly . Additionally, using TSEN2 antibodies in combination with RNA analysis techniques has helped researchers identify abnormal tRNA transcripts resulting from TSEN2 mutations or knockdown .

What are the optimal conditions for using TSEN2 antibodies in Western blot experiments?

For optimal Western blot results with TSEN2 antibodies:

• Sample preparation: TSEN2 has been successfully detected in human brain tissue, mouse brain tissue, and mouse colon tissue, as well as cell lines like HeLa .

• Protein loading: 35μg/lane has been documented to provide clear signal detection .

• Antibody dilution: Most TSEN2 antibodies work optimally at dilutions between 1:500-1:2000 for Western blot applications .

• Detection: TSEN2 typically appears at its predicted molecular weight of approximately 51 kDa .

• Controls: Knockdown or knockout samples provide excellent negative controls. Published studies have utilized siRNA-mediated knockdown of TSEN2 to validate antibody specificity .

It is recommended to titrate new antibody lots in each testing system to obtain optimal results .

How can researchers effectively validate TSEN2 antibody specificity?

Validating TSEN2 antibody specificity requires multiple complementary approaches:

• Knockdown/knockout validation: siRNA-mediated knockdown of TSEN2 followed by Western blot analysis should show reduced or absent signal compared to controls. This approach has been documented in published studies investigating TSEN complex assembly .

• Recombinant protein controls: Using purified recombinant TSEN2 protein as a positive control can help confirm antibody specificity .

• Multiple antibody approach: Using different antibodies targeting distinct epitopes of TSEN2 and observing consistent results strengthens validation.

• Immunoprecipitation followed by mass spectrometry: This approach can confirm that the antibody is specifically capturing TSEN2 and its known interaction partners (TSEN54, TSEN34, TSEN15) .

• Cross-reactivity testing: Testing the antibody against related proteins or in samples from different species to ensure specificity based on evolutionary conservation patterns .

What are the key considerations for immunofluorescence experiments using TSEN2 antibodies?

For successful immunofluorescence experiments with TSEN2 antibodies:

• Subcellular localization: TSEN2 is primarily localized in the nucleus and sometimes transiently in the nucleolus . Expect nuclear staining patterns with occasional nucleolar enrichment.

• Fixation methods: Standard paraformaldehyde fixation (4%) is typically effective for TSEN2 detection.

• Antibody dilution: Use dilutions between 1:50-1:500 for optimal signal-to-noise ratio in IF applications .

• Positive controls: HeLa cells have been documented to show positive IF/ICC detection with TSEN2 antibodies .

• Co-localization studies: Consider co-staining with markers for nucleoli (e.g., fibrillarin) or other tRNA processing factors to validate localization patterns.

• Signal validation: Compare staining patterns with siRNA knockdown controls to confirm specificity of the observed signal .

How can TSEN2 antibodies be used to investigate disease mechanisms in pontocerebellar hypoplasia?

TSEN2 mutations have been associated with pontocerebellar hypoplasia type 2B (PCH2B), characterized by an abnormally small cerebellum and brainstem, progressive microcephaly, extrapyramidal dyskinesia, chorea, and frequent epilepsy . Researchers can employ TSEN2 antibodies to:

• Compare TSEN2 protein levels and localization in patient-derived cells versus controls using Western blot and immunofluorescence.

• Perform immunoprecipitation studies to assess whether disease-associated mutations affect TSEN complex formation. Research has shown that in patient cell lines, there is a substantial reduction of co-immunoprecipitated TSEN2 and TSEN54 when using α-TSEN34 antibody, suggesting assembly defects contribute to disease pathogenesis .

• Investigate the impact of TSEN2 mutations on tRNA processing by combining TSEN2 immunoprecipitation with RNA-seq analysis of bound tRNAs.

• Conduct tissue-specific studies using immunohistochemistry to examine TSEN2 expression patterns in brain regions affected by PCH2B.

• Develop cellular or animal models expressing mutant TSEN2 and use antibodies to track protein expression, localization, and functional consequences.

What approaches can be used to study the interactions between TSEN2 and other components of the tRNA splicing endonuclease complex?

To study TSEN2 interactions within the tRNA splicing endonuclease complex:

• Co-immunoprecipitation: Use TSEN2 antibodies to pull down the complex and analyze co-precipitated proteins (TSEN54, TSEN34, TSEN15) by Western blot or mass spectrometry. Studies have shown that TSEN54 knockdown reduces TSEN2 protein levels, while TSEN2 knockdown also reduces TSEN54 protein, suggesting their interdependence .

• Proximity ligation assays: These can visualize and quantify protein-protein interactions between TSEN2 and other complex components within cells.

• Recombinant protein interaction studies: Research has demonstrated that reconstitution of the human tRNA splicing endonuclease complex can be achieved by co-expressing TSEN2 with other components. Using wild-type or mutant versions with specific active site mutations (Y369A, H377A, K416A in TSEN2) can help define functional interactions .

• Domain mapping: Using truncated versions of TSEN2 in interaction studies can help identify which domains are critical for complex assembly.

• Quantitative binding assays: Studies have employed fluorescence anisotropy and pull-down experiments with labeled tRNA substrates to determine binding parameters of the TSEN complex .

How can researchers investigate the catalytic activities of TSEN2 using specific antibodies?

To investigate TSEN2's catalytic activities:

• In vitro cleavage assays: Immunoprecipitate TSEN2-containing complexes using specific antibodies and assess their ability to cleave pre-tRNA substrates. Research has shown that mutation of the active sites within TSEN2 (Y369A, H377A, K416A) does not impair TSEN protein expression or complex formation but does affect function .

• Structure-function studies: Use antibodies against specific domains to block or detect conformational changes during catalysis.

• Catalytic site mutant analysis: Compare wild-type and catalytic site mutants (particularly His377, which acts as a general acid at the scissile phosphate of the exon-intron junction ) to understand the role of specific residues.

• RNA binding studies: Research has shown that catalytically inactive TSEN tetramers (with H377A mutation in TSEN2) can be used to study RNA binding parameters safely without cleaving the substrate .

• Temporal analysis: Use antibodies to track TSEN2 localization and activity during different phases of the cell cycle or under various cellular stresses.

What methods can be used to study the role of TSEN2 in the newly identified syndrome with atypical hemolytic uremic syndrome (aHUS)?

A recently identified intronic variant in TSEN2 causes a syndrome characterized by microcephaly, craniofacial malformations, growth and intellectual retardation, and atypical hemolytic uremic syndrome (aHUS) . Researchers can investigate this connection using:

• Patient sample analysis: Use TSEN2 antibodies to compare protein expression levels and patterns in patient-derived cells versus controls.

• RNA-seq analysis combined with TSEN2 immunoprecipitation: Research has revealed that bulk RNA sequencing of peripheral blood cells from affected individuals shows abnormal tRNA transcripts, indicating alterations in tRNA biogenesis .

• Splicing analysis: The mutation results in a complex combination of transcripts with retention of normally spliced transcript, transcripts with exon 10 skipping, and transcripts containing two extra amino acids . Researchers can use TSEN2 antibodies to pull down different protein isoforms for functional characterization.

• Zebrafish models: Morpholino-mediated skipping of exon 10 of tsen2 in zebrafish has been used to model aspects of the syndrome .

• Endothelial cell studies: Since aHUS involves endothelial cell dysfunction, researchers can investigate TSEN2 expression and function in endothelial cells using specific antibodies in combination with functional assays.

How can TSEN2 antibodies be utilized in studies of abnormal tRNA processing?

TSEN2 antibodies can be valuable tools for investigating abnormal tRNA processing:

• Immunoprecipitation followed by RNA-seq: This approach can identify abnormally processed tRNAs associated with TSEN2 mutations or dysregulation. Studies have demonstrated five abnormal tRNAs in affected individuals that are absent in healthy individuals, clearly indicating that TSEN2 mutations impair the function of the TSEN complex and modify the tRNA inventory .

• Analysis of tRNA fragments: Combine TSEN2 immunoprecipitation with small RNA sequencing to identify and characterize tRNA fragments generated by altered TSEN2 function.

• Co-localization studies: Use fluorescently labeled TSEN2 antibodies along with RNA FISH for specific tRNAs to track their processing in living cells.

• Tissue-specific analysis: Compare tRNA processing efficiency across different tissues using tissue microarrays and TSEN2 immunohistochemistry.

• In vitro reconstitution: Purify TSEN2-containing complexes using specific antibodies to perform controlled in vitro tRNA processing assays with wild-type or mutant pre-tRNAs.

What are common pitfalls in TSEN2 antibody-based experiments and how can they be addressed?

Common pitfalls and solutions in TSEN2 antibody experiments include:

• Non-specific binding: TSEN2 has 5 isoforms with molecular masses of 45-53 kDa , which can complicate interpretation of Western blot results. Solution: Use isoform-specific antibodies when possible, and carefully validate bands at different molecular weights.

• Low signal intensity: TSEN2 is expressed at very low levels in most tissues . Solution: Optimize protein extraction methods, increase antibody concentration, and extend incubation times or use signal amplification systems.

• Background in immunofluorescence: Nuclear proteins can sometimes show high background staining. Solution: Optimize blocking conditions, use monoclonal antibodies when available, and include appropriate controls.

• Antibody cross-reactivity: Some TSEN2 antibodies may cross-react with related proteins. Solution: Validate specificity using knockdown/knockout controls and test multiple antibodies targeting different epitopes.

• Variability between experiments: Different lots of the same antibody may perform differently. Solution: Standardize protocols, use consistent positive controls, and validate each new lot.

How can researchers optimize TSEN2 immunoprecipitation for studying protein-RNA interactions?

To optimize TSEN2 immunoprecipitation for protein-RNA interaction studies:

• Cross-linking approach: Use formaldehyde or UV cross-linking to stabilize protein-RNA interactions before cell lysis.

• RNase inhibition: Include potent RNase inhibitors in all buffers to preserve RNA integrity.

• Antibody selection: Choose TSEN2 antibodies raised against epitopes that are not involved in RNA binding to avoid interference with natural interactions.

• Elution conditions: Optimize elution conditions to maintain both protein and RNA integrity. For sequential analysis, consider eluting RNA and protein separately.

• Controls: Include IgG controls and, ideally, TSEN2 knockdown samples as negative controls.

• RNA analysis methods: Depending on the research question, analyze co-immunoprecipitated RNAs by RT-PCR, Northern blotting, or RNA-seq.

• Mutant analysis: Compare wild-type TSEN2 with catalytic mutants (e.g., H377A) that can bind but not cleave RNA substrates .

What are the latest advances in TSEN2 antibody-based research techniques?

Recent advances in TSEN2 antibody-based research techniques include:

• Proximity-dependent biotinylation (BioID or TurboID): By fusing TSEN2 with a biotin ligase, researchers can identify proteins that come into close proximity with TSEN2 in living cells.

• CRISPR-Cas9 engineered cell lines: Creating endogenously tagged TSEN2 (e.g., with FLAG or GFP) allows for more specific antibody-based detection without overexpression artifacts.

• Single-molecule RNA visualization: Combining TSEN2 immunofluorescence with single-molecule FISH enables visualization of TSEN2-tRNA interactions at the single-cell level.

• Mass spectrometry-based interactomics: Using TSEN2 antibodies for immunoprecipitation followed by mass spectrometry has revealed interactions between the tRNA splicing endonuclease and pre-mRNA 3'-end processing factors (CLP1, CPSF1, CPSF4, and CSTF2) .

• Patient-derived cellular models: TSEN2 antibodies are being used to characterize protein expression and localization in induced pluripotent stem cells (iPSCs) and derived neural cells from patients with TSEN2 mutations.

What are emerging research areas where TSEN2 antibodies will be particularly valuable?

Emerging research areas where TSEN2 antibodies will be particularly valuable include:

• Neurodevelopmental disorders: Given the association of TSEN2 mutations with pontocerebellar hypoplasia and other neurological conditions, TSEN2 antibodies will be crucial for studying neurodevelopmental mechanisms .

• Non-canonical functions: Beyond tRNA processing, research has revealed roles for TSEN in mRNA processing and potentially other RNA metabolism pathways .

• Tissue-specific tRNA processing: Investigating how TSEN2 function varies across different tissues may help explain the tissue-specific manifestations of TSEN2 mutations.

• Therapeutic development: As potential therapies targeting tRNA processing emerge, TSEN2 antibodies will be essential for validating target engagement and mechanism of action.

• Stress response mechanisms: Studying how cellular stresses affect TSEN2 localization and function may reveal new insights into translational regulation during stress.

How might TSEN2 antibody research contribute to understanding broader RNA processing mechanisms?

TSEN2 antibody research can contribute to broader RNA processing understanding through:

• Mechanistic insights: Studies have shown that the tRNA splicing endonuclease is involved in multiple RNA-processing events beyond tRNA splicing . TSEN2 antibodies can help elucidate these connections.

• Integration of pathways: Research has established links between pre-tRNA splicing and pre-mRNA 3'-end formation , suggesting integrated regulation of different RNA processing pathways.

• Evolution of RNA processing: Comparative studies using TSEN2 antibodies across species can illuminate the evolution of RNA processing mechanisms.

• Disease mechanisms: Understanding how TSEN2 mutations affect RNA processing may provide insights into disease mechanisms for conditions beyond those currently associated with TSEN2.

• Translational regulation: The impact of altered tRNA processing on translation efficiency represents an emerging area where TSEN2 antibody research could make significant contributions.